3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Cisplatin
4
trastuzumab deruxtecan
3
Platinum
3
Docetaxel
3
Carboplatin
3
Biopsy
3
pembrolizumab
2
entrectinib
2
darolutamide
2
Trastuzumab
2
Radiotherapy, Intensity-Modulated
2
Leuprolide
2
Goserelin
2
Ado-Trastuzumab Emtansine
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
trastuzumab biosimilar HLX02
1
sacituzumab govitecan
1
pyrotinib
1
pertuzumab
1
luprolide acetate gel depot
1
larotrectinib
1
enfortumab vedotin
1
dehydroftorafur
1
ceralasertib
1
camrelizumab
1
bicalutamide
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Erlotinib Hydrochloride
×
90 days
×
Clear all
No trials found.